|
1. |
Arterial Stiffness and Stroke in HypertensionTherapeutic Implications for Stroke Prevention |
|
CNS Drugs,
Volume 19,
Issue 1,
2005,
Page 1-11
Stéphane Laurent,
Pierre Boutouyrie,
Preview
|
PDF (221KB)
|
|
摘要:
Stroke is the second leading cause of mortality worldwide, and the leading cause of death in China and Japan. Its prevention represents a major goal. Identification of primary stroke risk, particularly through newly individualised risk factors including biomarkers of large artery damage such as arterial stiffening, is necessary for determining the appropriate level of intervention. The purpose of this review is to focus on the pathophysiology of arterial stiffness, its predictive value for stroke and the therapeutic implications of this risk factor for stroke prevention. The predictive value of arterial stiffness for stroke was demonstrated in a longitudinal study that included 1715 patients with essential hypertension and measurements of carotid-femoral pulse wave velocity (PWV) [an indicator of arterial stiffness] at entry. Over a mean follow-up period of 7.9 years, during which 25 fatal strokes occurred, PWV significantly predicted stroke (relative risk = 1.39 [(95% CI 1.08, 1.72]; p = 0.02 for each 4 m/sec increase) independently of classical cardiovascular risk factors, including age, cholesterol level, diabetes mellitus, smoking and mean blood pressure. Additional longitudinal studies are needed to confirm the predictive value of aortic stiffness on primary and secondary events, in low- and high-risk populations, in various countries, and using different methodologies of arterial stiffness measurement. Drug treatment could prevent stroke through a reduction in arterial stiffness in parallel with correction of cardiovascular risk factors such as hypertension, dyslipidaemia, diabetes mellitus and smoking, all of which are associated with arterial stiffening. In view of the important local actions of angiotensin II on arterial stiffening, drugs interfering with the renin-angiotensin-aldosterone system should be particularly effective. Promising therapeutic strategies to reduce arterial stiffness include taking advantage of the non-lipid-lowering effects of statins and directly targeting the molecular events leading to arterial stiffening, such as formation of advanced glycation end products.
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
2. |
Novel Approaches to the Treatment of Cocaine Addiction |
|
CNS Drugs,
Volume 19,
Issue 1,
2005,
Page 13-25
Mehmet Sofuoglu,
Thomas R Kosten,
Preview
|
PDF (179KB)
|
|
摘要:
Cocaine addiction continues to be an important public health problem with over 1.7 million users in the US alone. Although there are no approved pharmacotherapies for cocaine addiction, a number of medications have been tested with some promising results. In this review, we summarise some of the emerging targets for cocaine pharmacotherapy including dopaminergic and GABA medications, adrenoceptor antagonists, vasodilators and immunotherapies. The brain dopamine system plays a significant role in mediating the rewarding effects of cocaine. Among dopaminergic agents tested for cocaine pharmacotherapy, disulfiram has decreased cocaine use in a number of studies. Amantadine, another medication with dopaminergic effects, may also be effective in cocaine users with high withdrawal severity. GABA is the main inhibitory neurotransmitter in the brain, and accumulating evidence suggests that the GABA system modulates the dopaminergic system and cocaine effects. Two anticonvulsant medications with GABAergic effects, tiagabine and topiramate, have yielded positive findings in clinical trials. Baclofen, a GABABreceptor agonist, is also promising, especially in those with more severe cocaine use. Some of the physiological and behavioural effects of cocaine are mediated by activation of the adrenergic system. In cocaine users, propranolol, a β-adrenoceptor antagonist, had promising effects in individuals with more severe cocaine withdrawal symptoms. Cerebral vasodilators are another potential target for cocaine pharmacotherapy. Cocaine users have reduced cerebral blood flow and cortical perfusion deficits. Treatment with the vasodilators amiloride or isradipine has reduced perfusion abnormalities found in cocaine users. The functional significance of these improvements needs to be further investigated. All these proposed pharmacotherapies for cocaine addiction act on neural pathways. In contrast, immunotherapies for cocaine addiction are based on the blockade of cocaine effects peripherally, and as a result, prevent or at least slow the entry of cocaine into the brain. A cocaine vaccine is another promising treatment for cocaine addiction. The efficacy of this vaccine for relapse prevention is under investigation. Many initial promising findings need to be replicated in larger, controlled clinical trials.
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
3. |
Switching Between Second-Generation AntipsychoticsWhy and How? |
|
CNS Drugs,
Volume 19,
Issue 1,
2005,
Page 27-42
Monika Edlinger,
Susanne Baumgartner,
Nadja Eltanaihi-Furtmüller,
Martina Hummer,
W Wolfgang Fleischhacker,
Preview
|
PDF (241KB)
|
|
摘要:
The introduction of second-generation antipsychotics represents an important advance in the treatment of schizophrenia. Although these drugs are generally very effective, not all patients respond in the same way. Partial response with persistent positive and negative symptoms and residual symptoms may force physicians to change antipsychotic medication. As more and more second-generation antipsychotics are introduced, the need for practical guidelines on switching these medications becomes increasingly important.In this article we provide a short summary of the second-generation antipsychotics, focusing on efficacy, adverse effect profile and safety. Indications for switching antipsychotic medication are outlined, as well as recommendations when switching is disadvantageous. Three basic switching strategies (abrupt, gradual and overlapping switching) and their potential risks and benefits are described. We review the available evidence concerning techniques, problems and consequences when switching from one second-generation antipsychotic agent to another and discuss potential difficulties.
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
4. |
Efficacy and Tolerability of Reboxetine in Depressive Patients Treated in Routine Clinical Practice |
|
CNS Drugs,
Volume 19,
Issue 1,
2005,
Page 43-54
Thomas Messer,
Max Schmauss,
Judith Lambert-Baumann,
Preview
|
PDF (236KB)
|
|
摘要:
ObjectivesReboxetine, a potent and selective noradrenaline reuptake inhibitor, has been approved for treatment of major depression. The aim of this study was to investigate the efficacy and tolerability of reboxetine in depressive outpatients undergoing treatment in routine clinical practice.Study design and methodsThis post-marketing surveillance study was conducted to evaluate the therapeutic efficacy and tolerability of standard therapeutic doses of reboxetine in patients with depressive symptoms, particularly when administered in routine clinical practice. The 1835 patients (mean 54 years of age) evaluated showed demographic characteristics representative of the general depressive population. The majority of patients received the recommended dose of reboxetine 8 mg/day.ResultsMeasures of efficacy showed improvement in depressive symptoms with reboxetine therapy over the mean observational period of 9.6 weeks. Response to therapy, defined as Hamilton depression scale 21-item version score reduction of ≥50%, was reported in 83% of patients. The effects of reboxetine were rated by physicians as ‘good’ or ‘very good’ in 86% of patients at the last visit. The tolerability of reboxetine was rated by physicians as ‘good’ or ‘very good’ in 92% of patients at all evaluations. No adverse events that were possibly related to reboxetine therapy occurred in >1% of patients.ConclusionThe results of this study suggest that reboxetine is safe and well tolerated and may improve symptoms in depressive patients treated in routine clinical practice.
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
5. |
Intramuscular Interferon-β-1aIn Patients at High Risk of Developing Clinically Definite Multiple Sclerosis |
|
CNS Drugs,
Volume 19,
Issue 1,
2005,
Page 55-61
M Asif A Siddiqui,
Keri Wellington,
Preview
|
PDF (272KB)
|
|
摘要:
▴ Intramuscular interferon-β-1a, a recombinant interferon-β approved in the US for the treatment of relapsing forms of multiple sclerosis (MS), has also been evaluated in the treatment of patients with a first clinical demyelinating episode and brain lesions consistent with MS confirmed by magnetic resonance imaging (MRI).▴ In a randomised, double-blind trial, patients at high risk of developing clinically definite MS who received intramuscular interferon-β-1a 30μg once weekly had a 44% reduction in the cumulative probability of developing MS, compared with placebo recipients (rate ratio 0.56; p = 0.002), over a 3-year period after a first, MRI-confirmed demyelinating event.▴ These results were supported by MRI findings that showed significantly smaller increases in the volume of brain lesions and the number of new/enlarging and gadolinium-enhancing lesions in interferon-β-1a recipients than in those receiving placebo.▴ A nonblind extension of this trial demonstrated that early treatment with interferon-β-1a significantly reduced the probability of developing MS by 35% (p = 0.03), compared with delayed treatment, over a 5-year period.▴ Intramuscular interferon-β-1a was generally well tolerated; however, influenza-like syndrome was documented in >50% of patients at high risk of developing clinically definite MS who received the drug.Table. Features and properties of intramuscular interferon-β-1a (Avonex®)
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
6. |
Intramuscular Interferon-β-1a: In Patients at High Risk of Developing Clinically Definite Multiple SclerosisA Viewpoint by Peter Flachenecker |
|
CNS Drugs,
Volume 19,
Issue 1,
2005,
Page 63-64
Peter Flachenecker,
Preview
|
PDF (146KB)
|
|
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
7. |
ZolpidemA Review of Its Use in the Management of Insomnia |
|
CNS Drugs,
Volume 19,
Issue 1,
2005,
Page 65-89
Tracy Swainston Harrison,
Gillian M Keating,
Preview
|
PDF (362KB)
|
|
摘要:
Zolpidem (Ambien®, Stilnox®, Myslee®), an imidazopyridine, is a nonbenzodiazepine hypnotic indicated for the short-term treatment of insomnia.Zolpidem improves sleep in patients with insomnia. Its overall tolerability is favourable when administered according to the manufacturer's prescribing information, with a low propensity to cause clinical residual effects, withdrawal, dependence or tolerance. In addition, most evidence suggests that the drug is associated with minimal rebound insomnia. In the only clinical trials that investigated the use of a hypnosedative drug in an ‘as-needed’ regimen, zolpidem produced a global improvement in sleep. Thus, zolpidem continues to be a useful therapeutic option in the pharmacological treatment of patients with insomnia.
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
|